The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20

Journal of Immunology

Volumn 177, Issue 1, 2006, Pages 362-371

  Teeling, Jessica L ^b   Mackus, Wendy J M ^a   Wiegman, Luus J J M ^a   Van Den Brakel, Jeroen H N ^a   Beers, Stephen A ^b   French, Ruth R ^b   Van Meerten, Tom ^c   Ebeling, Saskia ^c   Vink, Tom ^a   Slootstra, Jerry W ^d   Parren, Paul W H I ^a   Glennie, Martin J ^a,b   Van De Winkel, Jan G J ^a,c  

^a GENMAB   (Netherlands)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Pepscan Systems   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CD20 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENTARY DNA; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; PROLINE; RETROVIRUS VECTOR; RITUXIMAB; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; VIRUS PARTICLE; WESTERN BLOTTING;

EID: 33745324686     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.1.362     Document Type: Article

References (44)

1. Tedder, T. F., and P. Engel. 1994. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15: 450-454.
2. Liang, Y., T. R. Buckley, L. Tu, S. D. Langdon, and T. F. Tedder. 2001. Structural organization of the human MS4A gene cluster on chromosome 11q12. Immunogenetics 53: 357-368.
3. Cragg, M. S., C. A. Walshe, A. O. Ivanov, and M. J. Glennie. 2005. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8: 140-174.
4. Li, H., L. M. Ayer, J. Lytton, and J. P. Deans. 2003. Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. 278: 42427-42434.
5. O'Keefe, T. L., G. T. Williams, S. L. Davies, and M. S. Neuberger. 1998. Mice carrying a CD20 gene disruption. Immunogenetics 48: 125-132.
6. Coiffier, B. 2003. Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma. Curr. Hematol. Rep. 2: 23-29.
7. Coiffier, B. 2004. Rituximab in diffuse large B-cell lymphoma. Clin. Adv. Hematol. Oncol. 2: 156-157.
8. Johnson, P., and M. Glennie. 2003. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. 30: 3-8.
9. Glennie, M. J., and J. G. van de Winkel. 2003. Renaissance of cancer therapeutic antibodies. Drug Discov. Today 8: 503-510.
10. Cheson, B. D. 2006. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol. Immunother. 55: 188-196.
11. Summers, K. M., and D. R. Kockler. 2005. Rituximab treatment of refractory rheumatoid arthritis. Ann. Pharmacother. 39: 2091-2095.
12. Manshouri, T., K. A. Do, X. Wang, F. J. Giles, S. M. O'Brien, H. Saffer, D. Thomas, I. Jilani, H. M. Kantarjian, M. J. Keating, and M. Albitar. 2003. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101: 2507-2513.
13. Beum, P. V., A. D. Kennedy, and R. P. Taylor. 2004. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Methods 289: 97-109.
14. Jilani, I., S. O'Brien, T. Manshuri, D. A. Thomas, V. A. Thomazy, M. Imam, S. Naeem, S. Verstovsek, H. Kantarjian, F. Giles, et al. 2003. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 102: 3514-3520.
15. Kennedy, A. D., P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172: 3280-3288.
16. Beum, P. V., A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor. 2006. The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176: 2600-2609.
17. Press, O. W., F. Appelbaum, J. A. Ledbetter, P. J. Martin, J. Zarling, P. Kidd, and E. D. Thomas. 1987. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69: 584-591.
18. Cragg, M. S., R. R. French, and M. J. Glennie. 1999. Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 11: 541-547.
19. Ghetie, M. A., H. Bright, and E. S. Vitetta. 2001. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97: 1392-1398.
20. Pagel, J. M., C. Laugen, L. Bonham, R. C. Hackman, D. M. Hockenbery, R. Bhatt, D. Hollenback, H. Carew, J. W. Singer, and O. W. Press. 2005. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-β and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin. Cancer Res. 11: 4857-4866.
21. Shan, D., A. K. Gopal, and O. W. Press. 2001. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Clin. Cancer Res. 7: 2490-2495.
22. Shan, D., J. A. Ledbetter, and O. W. Press. 2000. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48: 673-683.
23. Byrd, J. C., S. Kitada, I. W. Flinn, J. L. Aron, M. Pearson, D. Lucas, and J. C. Reed. 2002. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99: 1038-1043.
24. Chan, H. T., D. Hughes, R. R. French, A. L. Tutt, C. A. Walshe, J. L. Teeling, M. J. Glennie, and M. S. Cragg. 2003. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res. 63: 5480-5489.
25. Cragg, M. S., S. M. Morgan, H. T. Chan, B. P. Morgan, A. V. Filatov, P. W. Johnson, R. R. French, and M. J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101: 1045-1052.
26. Teeling, J. L., R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
27. Polyak, M. J., S. H. Tailor, and J. P. Deans. 1998. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J. Immunol. 161: 3242-3248.
28. Polyak, M. J., and J. P. Deans. 2002. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99: 3256-3262.
29. Perosa, F., E. Favoino, M. A. Caragnano, and F. Dammacco. 2005. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3B precursor. Blood 107: 1070-1077.
30. 1 phase of the cell cycle. J. Immunol. 135: 3795-3801.
31. Tedder, T. F., A. Forsgren, A. W. Boyd, L. M. Nadler, and S. F. Schlossman. 1986. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur. J. Immunol. 16: 881-887.
32. Deans, J. P., S. M. Robbins, M. J. Polyak, and J. A. Savage. 1998. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J. Biol. Chem. 273: 344-348.
33. Weijtens, M., A. van Spronsen, A. Hagenbeek, E. Braakman, and A. Martens. 2002. Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats. Hum. Gene Ther. 13: 187-198.
34. Tutt, A. L., R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. Parkhouse, G. G. Klaus, and M. J. Glennie. 1998. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161: 3176-3185.
35. Slootstra, J. W., W. C. Puijk, G. J. Ligtvoet, J. P. Langeveld, and R. H. Meloen. 1996. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol. Divers. 1: 87-96.
36. Timmerman, P., J. Beld, W. C. Puijk, and R. H. Meloen. 2005. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. Chembiochem. 6: 821-824.
37. Fishwild, D. M., S. L. O'Donnell, T. Bengoechea, D. V. Hudson, F. Harding, S. L. Bernhard, D. Jones, R. M. Kay, K. M. Higgins, S. R. Schramm, and N. Lonberg. 1996. High-avidity human IgGK monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14: 845-851.
38. 2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 121: 1121-1132.
39. Hagenbeek, A., T. Plesner, J. Walewski, A. Hellmanni B. K. Link, and L. W. Dalby. 2004. HuMax-CD20 fully human monoclonal antibody in follicular lymphoma: first human exposure: early results of an ongoing phase I/II trial. Blood 104: 1400.
40. Golay, J., M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna. 2001. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98: 3383-3389.
41. Leveille, C., R. AL-Daccak, and W. Mourad. 1999. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur. J. Immunol. 29: 65-74.
42. Szollosi, J., V. Horejsi, L. Bene, P. Angelisova, and S. Damjanovich. 1996. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J. Immunol. 157: 2939-2946.
43. Saphire, E. O., R. L. Stanfield, M. D. Crispin, P. W. Parren, P. M. Rudd, R. A. Dwek, D. R. Burton, and I. A. Wilson. 2002. Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319: 9-18.
44. 2 antibody containing thioether-linked Fab'γ fragments. J. Immunol. 139: 2367-2375.